Seegene, Inc.
Financials
Valuation Metrics
Seegene, Inc.'s Market Cap is ₩1.5T. At end of 2025 it was ₩1.1T. Ranked #234 of 2,405 in KR market (top 10%), #51 of 1,627 on KOSDAQ (top 3%), #22 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 10%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 1.52T KRW | KR#234/2,405 Sec#22/231 |
| Revenue | 509.27B KRW | KR#614/2,405 Sec#32/231 |
| Net Income | 80.29B KRW | KR#294/2,405 Sec#20/231 |
| Total Assets | 1.27T KRW | KR#418/2,405 Sec#21/231 |
| Net Assets | 1.04T KRW | KR#287/2,405 Sec#16/231 |
| Employees | 862 | KR#292/2,405 Sec#23/231 |
| Value | ||
| P/E | 18.92x | KR#1,186/2,405 Sec#71/231 |
| P/B | 1.46x | KR#1,806/2,405 Sec#127/231 |
| P/S | 2.98x | KR#1,999/2,405 Sec#126/231 |
| EV/EBITDA | 21.54x | KR#1,076/2,405 Sec#66/231 |
| FCF Yield | 7.37% | KR#745/2,405 Sec#36/231 |
| Profitability | ||
| ROE | 7.72% | KR#816/2,405 Sec#55/231 |
| ROA | 6.34% | KR#593/2,405 Sec#48/231 |
| Op. Margin | 12.11% | KR#412/2,405 Sec#35/231 |
| Revenue Growth | 12.12% | KR#793/2,405 Sec#78/231 |
| Financial Health | ||
| Debt Ratio | 21.81% | KR#408/2,405 Sec#50/231 |
| Total Debt | 76.33B KRW | KR#828/2,405 Sec#53/231 |
| FCF | 111.98B KRW | KR#182/2,405 Sec#9/231 |
| Cash | 266.52B KRW | KR#218/2,405 Sec#6/231 |
| Current Ratio | 4.62x | KR#311/2,405 Sec#53/231 |
| Net Debt/EBITDA | -3.08x | KR#158/2,405 Sec#5/231 |
| Dividend | ||
| Div. Yield | 3.07% | KR#668/2,405 Sec#32/231 |
| Div. Growth | 25.00% | KR#390/2,405 Sec#20/231 |
| Performance | ||
| 1Y Return | 28.46% | KR#277/2,405 Sec#17/231 |
| 1M Return | -11.92% | KR#1,330/2,405 Sec#131/231 |
| From 52W High | -19.65% | KR#182/2,405 Sec#10/231 |
| 1Y MDD | -23.60% | KR#113/2,405 Sec#7/231 |
| Trading | ||
| Volume | 200,667 shares | KR#370/2,405 Sec#34/231 |
| Trading Value | 6.61B KRW | KR#262/2,405 Sec#18/231 |
| Foreign Own. | 18.72% | KR#247/2,405 Sec#13/231 |
| Per Share | ||
| EPS | 1,718 KRW | KR#497/2,405 Sec#32/231 |
| BPS | 22,241 KRW | KR#493/2,405 Sec#35/231 |
Company Info
Seegene, established in 2000 and headquartered in Songpa-gu, Seoul, focuses on developing gene analysis technology and reagents. The company engages in the development, manufacturing, and sales of molecular diagnostic reagents that identify disease causes through gene analysis, possessing high-multiplex syndromic quantitative PCR technology. With agencies in over 100 countries including Italy, UAE, USA, and Canada, Seegene is actively expanding its global sales network and acquired 100% of Dandi Meka's shares in 2025.